Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- dospělí MeSH
- fenylmočovinové sloučeniny aplikace a dávkování MeSH
- indoly aplikace a dávkování MeSH
- karcinom z renálních buněk farmakoterapie mortalita patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory ledvin farmakoterapie mortalita patologie MeSH
- niacinamid aplikace a dávkování analogy a deriváty MeSH
- přežití po terapii bez příznaků nemoci MeSH
- progrese nemoci MeSH
- protokoly antitumorózní kombinované chemoterapie aplikace a dávkování MeSH
- pyrroly aplikace a dávkování MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sorafenib MeSH
- sunitinib MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- fenylmočovinové sloučeniny MeSH
- indoly MeSH
- niacinamid MeSH
- pyrroly MeSH
- sorafenib MeSH
- sunitinib MeSH
Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known. A retrospective, registry-based study has been carried out to assess correlation between clinical response and progression-free survival in patients with mRCC treated sequentially with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. Data on 218 mRCC patients treated with sunitinib and sorafenib who completed therapy with both TKIs were obtained from a database of mRCC patients. Standard nonparametric methods were used to assess correlation between response, PFS and length of treatment on the two agents. A strong correlation between responses to first- versus second TKI was observed (p < 0.001). No significant association was noted between the duration of therapy with the two TKIs (p = 0.056), although there was a weak statistically significant correlation between progression-free survival times in the subgroup patients who discontinued treatment because of disease progression. In conclusion, the duration of response on first TKI is of limited value in selecting mRCC patients for sequential TKI therapy. There is a strong correlation between the types of tumour response on the first- versus the second TKI.
Zobrazit více v PubMed
Ann Oncol. 2012 Feb;23(2):395-401 PubMed
N Engl J Med. 2007 Jan 11;356(2):115-24 PubMed
Lancet. 2008 Aug 9;372(9637):449-56 PubMed
Lancet. 2011 Dec 3;378(9807):1931-9 PubMed
N Engl J Med. 2007 Jan 11;356(2):125-34 PubMed
Target Oncol. 2013 Sep;8(3):203-209 PubMed
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy
